Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antiv...Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.展开更多
The direct acting antivirals(DAAs)are now the standard of care for hepatitis C virus(HCV)treatment with high and effective sustained virologic responserate(SVR)and great safety profile,including solid organ transplant...The direct acting antivirals(DAAs)are now the standard of care for hepatitis C virus(HCV)treatment with high and effective sustained virologic responserate(SVR)and great safety profile,including solid organ transplant patients.There are increasing reports showing DAAs are effective with high SVR rates and safety profile in kidney transplant recipients.There are reports on drug-drug interaction(DDI)between tacrolimus with DAAs.However,data remain lacking on potential DDIs between tacrolimus and DAA regimens and the management process.This case series reports three kidney transplant patients on tacrolimus who were successfully treated for HCV with multidisciplinary approach,although there was DDI between tacrolimus with sofosbuvir/velpatasvir and glecaprevir/pibrentasvir,which required tacrolimus dose adjustment to maintain therapeutic level during and after DAA treatment.Such DDIs should be aware of and closely monitored by pharmacist and physicians with tacrolimus dose adjustment as needed during and right after DAA treatment in post-kidney transplant patients.展开更多
Hepatitis C virus(HCV)infection is a major cause of end-stage liver disease,including decompensated cirrhosis and hepatocellular carcinoma.Over 95%of patients with HCV infection have achieved sustained virologic respo...Hepatitis C virus(HCV)infection is a major cause of end-stage liver disease,including decompensated cirrhosis and hepatocellular carcinoma.Over 95%of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved for patients with HCV infection.The glecaprevir/pibrentasvir(G/P)regimen has some features that distinguish it from others and is the only 8-week regimen approved for treatment-naive patients and patients experienced in regimens containing(peg)interferon,ribavirin,and/or sofosbuvir,without an HCV NS3/4A protease inhibitor or NS5A inhibitor(except those with genotype 3).This review aims to summarize the efficacy and safety of G/P in HCV-infected patients from clinic trials and real-world studies,including those who have historically been considered difficult to cure.展开更多
Background and Aims:Glecaprevir/pibrentasvir is a pangenotypic regimen recently approved for the treatment of chronic hepatitis C virus(HCV)infection.The objective of the present review was to summarize the findings f...Background and Aims:Glecaprevir/pibrentasvir is a pangenotypic regimen recently approved for the treatment of chronic hepatitis C virus(HCV)infection.The objective of the present review was to summarize the findings from clinical trials to understand how patient-related factors influence glecaprevir/pibrentasvir efficacy(sustained virologic response rates at 12 weeks’after treatment[referred to as SVR12])and safety.Methods:Data from 21 phase III clinical trials were analyzed.Results:The integrated efficacy analysis included 4,817 patients.Findings showed 97.5%of all included patients with chronic HCV achieved SVR12 in the intention-to-treat population.SVR12 rate was>95%across subgroups of interest.The integrated safety analysis included 4,015 patients.Findings showed that 64.1%of patients reported an adverse event,and<0.1%of patients reported a serious adverse event related to glecaprevir/pibrentasvir.Conclusions:These results indicate that the 8-or 12-week glecaprevir/pibrentasvir treatment is effective for patients infected with HCV genotypes 1-6 without or with compensated cirrhosis,with good safety profiles,irrespective of treatment-experience.Glecaprevir/pibrentasvir is a good option for patients with human immunodeficiency virus/HCV coinfection and comorbid HCV and severe renal impairment.展开更多
文摘Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.
文摘The direct acting antivirals(DAAs)are now the standard of care for hepatitis C virus(HCV)treatment with high and effective sustained virologic responserate(SVR)and great safety profile,including solid organ transplant patients.There are increasing reports showing DAAs are effective with high SVR rates and safety profile in kidney transplant recipients.There are reports on drug-drug interaction(DDI)between tacrolimus with DAAs.However,data remain lacking on potential DDIs between tacrolimus and DAA regimens and the management process.This case series reports three kidney transplant patients on tacrolimus who were successfully treated for HCV with multidisciplinary approach,although there was DDI between tacrolimus with sofosbuvir/velpatasvir and glecaprevir/pibrentasvir,which required tacrolimus dose adjustment to maintain therapeutic level during and after DAA treatment.Such DDIs should be aware of and closely monitored by pharmacist and physicians with tacrolimus dose adjustment as needed during and right after DAA treatment in post-kidney transplant patients.
基金supported in part by the Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University.
文摘Hepatitis C virus(HCV)infection is a major cause of end-stage liver disease,including decompensated cirrhosis and hepatocellular carcinoma.Over 95%of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved for patients with HCV infection.The glecaprevir/pibrentasvir(G/P)regimen has some features that distinguish it from others and is the only 8-week regimen approved for treatment-naive patients and patients experienced in regimens containing(peg)interferon,ribavirin,and/or sofosbuvir,without an HCV NS3/4A protease inhibitor or NS5A inhibitor(except those with genotype 3).This review aims to summarize the efficacy and safety of G/P in HCV-infected patients from clinic trials and real-world studies,including those who have historically been considered difficult to cure.
基金sponsored by the National Natural Science Foundation of China(Grant Nos.81972265,81700534)the National Key Research Plan“Precision Medicine Research”Key Project(2017YFC0908103,2017YFC0908104,2018ZX10302206)+3 种基金the National Science and Technology Major Project(2017ZX10202202)the JLU Norman Bethune Research Plan(2018B32)the Program for JLU Science and Technology Innovative Research Team(2017TD-08)the Fundamental Research Funds for the Central Universities.
文摘Background and Aims:Glecaprevir/pibrentasvir is a pangenotypic regimen recently approved for the treatment of chronic hepatitis C virus(HCV)infection.The objective of the present review was to summarize the findings from clinical trials to understand how patient-related factors influence glecaprevir/pibrentasvir efficacy(sustained virologic response rates at 12 weeks’after treatment[referred to as SVR12])and safety.Methods:Data from 21 phase III clinical trials were analyzed.Results:The integrated efficacy analysis included 4,817 patients.Findings showed 97.5%of all included patients with chronic HCV achieved SVR12 in the intention-to-treat population.SVR12 rate was>95%across subgroups of interest.The integrated safety analysis included 4,015 patients.Findings showed that 64.1%of patients reported an adverse event,and<0.1%of patients reported a serious adverse event related to glecaprevir/pibrentasvir.Conclusions:These results indicate that the 8-or 12-week glecaprevir/pibrentasvir treatment is effective for patients infected with HCV genotypes 1-6 without or with compensated cirrhosis,with good safety profiles,irrespective of treatment-experience.Glecaprevir/pibrentasvir is a good option for patients with human immunodeficiency virus/HCV coinfection and comorbid HCV and severe renal impairment.
